NEW YORK (GenomeWeb News) – Molecular dermatology company HairDx, a subsidiary of PharmaGenoma, has launched a Belgian subsidiary to market its hair loss predictive test products in Europe, the company said today.

PharmaGenoma said that the HairDx Europe subsidiary will offer throughout Europe its genetic test for Androgenetic Alopecia, which the company said is the most common cause of hair loss in both men and women. The company noted that it has recently struck distribution agreements for the HairDX test in Italy and Japan.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.